IDEAYA Biosciences (IDYA) Net Income towards Common Stockholders (2018 - 2026)

IDEAYA Biosciences has disclosed Net Income towards Common Stockholders across 9 years of filings, most recently posting -$108.5 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$108.5 million, down 28.62% year-over-year; the trailing twelve-month figure through Mar 2026 was -$183.5 million (up 49.09% YoY), and the FY2025 annual result was -$159.3 million, up 51.28% from the prior year.
• Net Income towards Common Stockholders came in at -$108.5 million for Q1 2026 at IDEAYA Biosciences, down from -$94.6 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $108.5 million in Q3 2025 to a low of -$144.1 million in Q4 2024.
• The 5-year median for Net Income towards Common Stockholders is -$41.9 million (2023), against an average of -$46.6 million.
• Across the five-year window, Net Income towards Common Stockholders slumped 5179.7% in 2023 and surged 262.13% in 2025, its largest moves.
• IDEAYA Biosciences' Net Income towards Common Stockholders stood at -$26.4 million in 2022, then tumbled by 58.52% to -$41.9 million in 2023, then slumped by 243.87% to -$144.1 million in 2024, then soared by 34.39% to -$94.6 million in 2025, then fell by 14.78% to -$108.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$108.5 million (Q1 2026), -$94.6 million (Q4 2025), and $108.5 million (Q3 2025), per Business Quant data.